Data from the QUASAR long-term extension study demonstrate more than 70% of patients were in clinical remission and more than 40% of patients were in endoscopic remission at Week 92 Data from the ...

For patients who experience endoscopic remission of ulcerative colitis (UC), signs of active disease on histology did not affect their risk of clinical relapse, according to a large prospective study ...

In patients with ulcerative colitis who had endoscopic healing, achieving transmural healing was associated with longer relapse-free survival. Women and those who had received multiple advanced ...

Intestinal ultrasound (IUS) is non-invasive, cost-effective, and accurate to determine disease activity in ulcerative colitis (UC). In this study, we prospectively evaluated IUS for treatment response ...

For people with UC, ‘feeling better’ is just the start. Learn why tissue-level (histological) healing is becoming the new gold standard for UC remission and cancer prevention.

More than 80% of those treated with TREMFYA ® were in clinical remission and more than 50% were in endoscopic remission at Week 140 of the QUASAR long-term extension study, showing lasting disease ...

Icotrokinra demonstrated clinically meaningful outcomes at Week 28 in the Phase 2b ANTHEM-UC study in ulcerative colitis, with 31.7% of patients achieving clinical remission and 38.1% showing ...

While infliximab (Remicade) and vedolizumab (Entyvio) were comparable for clinical remission in previously biologic-naive ulcerative colitis patients, infliximab was more likely to result in ...

The American Gastroenterological Association has updated guidance for the treatment of ulcerative colitis to recommend using higher efficacy drugs in earlier stages of treatment, Medscape Medical News ...

Takeda presented promising data on its ulcerative colitis and Crohn’s disease drug Entyvio at the World Congress of Gastroenterology at ACG2017, Oct. 13 to Oct. 18 in Orlando, Fla. The data suggests ...

STOCKHOLM, Feb. 21, 2026 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) today announced new long-term data from the QUASAR long-term extension (LTE) study showing that TREMFYA® (guselkumab) sustained ...

The study also showed that of those in clinical remission at Week 44, 87.5% maintained clinical remission through Week 140. Efficacy was sustained regardless of prior biologic and/or JAK inhibitor ...